Abstract:e15557 Background: Fruquintinib, an antiangiogenic tyrosine kinase inhibitor (TKI), has demonstrated its significant survival benefits in metastatic colorectal cancer (mCRC) patients in both China and global phase III trials (FRESCO and FRESCO-2), but data on patients' health-related quality of life (HRQoL) was rare. A previous study on HRQoL of mCRC patients receiving another antiangiogenic TKI or placebo showed a decreased pattern in the mean utility index (UI) score of EuroQol 5-dimension (EQ-5D). This study intended to evaluate the HRQoL of mCRC patients receiving fruquintinib in the real world and describe its real-world treatment outcomes and compliance. Methods: This is a multicenter prospective observational study of patients with mCRC who were treated with fruquintinib monotherapy. Patient demographics, disease characteristics, and treatment history were recorded at baseline (before fruquintinib administration). Dosage record, treatment outcome, and HRQoL, which was measured by EQ-5D-5L scale and then converted to UI score, were recorded in each cycle. The UI score was described in total patients. The changes of it from baseline at key point (first cycle of fruquintinib) and end point (last cycle of fruquintinib) between subgroups, including prior use of VEGF inhibitors, RAS mutation status, etc, were compared by T-test or Wilcoxon rank sum test. Median progression-free survival (mPFS) was calculated using Kaplan-Meier method. The medication compliance rate was summarized according to the dosage record. Results: Data of 70 patients from five centers between May 2021 and November 2022 were evaluated in this study. Fruquintinib was used in second line treatment in 15.7% cases (N = 11), and in third or later line in 84.3% cases (N = 59). The median UI scores of EQ-5D-5L were 0.89, 0.78 and 0.73 at baseline (N = 70), key point of follow-up (N = 62) and end point of follow-up (N = 23), respectively. There was no significant difference between subgroups in median UI score changes from baseline, such as whether VEGF inhibitors were used previously or not (at key point, -0.07 vs. -0.11, p = 0.82, at end point, -0.21 vs. -0.26, p = 0.27), and whether RAS mutation or not (at key point, -0.02 vs. -0.04, p = 0.79, at end point, -0.21 vs. –0.16, p = 0.62). The mPFS of the total population was 4.8 months (N = 69, 95%CI 3.5-6.2), numerically longer than mPFS in FRESCO and FRESCO-2 trials. The mean actual (actual doses per cycle/21 days) and prescribed daily doses were 4.46 mg and 4.65 mg for 21 out of 28 days per patient, respectively. The compliance rate (actual/prescribed) of fruquintinib was 95.91%. Conclusions: As with the previous study, fruquintinib showed a similar gradually declined trend in HRQoL, which may be associated with disease deterioration in heavily pretreated mCRC patients. Fruquintinib has prolonged mPFS with good compliance in clinical practice.

A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice

A phase IV study to evaluate the safety of fruquintinib in Chinese real-world clinical practice.

Fruquintinib in refractory metastatic colorectal cancer: a multicenter real-world study

OA11.03 A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non‒Small-Cell Lung Cancer.

Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial

Fruquintinib in metastatic colorectal cancer: a multicenter real-world analysis on efficacy, safety, and predictive and prognostic factors

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China

A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

Quality of life, effectiveness, and compliance of fruquintinib in the treatment of metastatic colorectal cancer: Results from a prospective real-world study.

Fruquintinib with Gefitinib As First-Line Therapy in Patients Carrying EGFR Mutations with Advanced Non-Small Cell Lung Cancer: a Single-Arm, Phase II Study

JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial.

A Phase 1b Study of VEGFR Inhibitor Fruquintinib in Patients with Pretreated Advanced Colorectal Cancer.

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centered Phase 3 Trial Comparing Fruquintinib Versus Placebo Plus Best Supportive Care In Chinese Patients With Metastatic Colorectal Cancer (Fresco).

Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer

Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.

Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.

Subgroup Analysis by Prior Anti-Vegf or Anti-Egfr Target Therapy in FRESCO, a Randomized, Double-Blind, Phase 3 Trial Comparing Fruquintinib Versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer (Mcrc).